NasdaqGM - Nasdaq Real Time Price USD
Alvotech (ALVO)
At close: October 21 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
306,769.00
91,434.00
83,029.00
36,772.00
66,616.00
Cost of Revenue
158,114.00
160,856.00
64,095.00
--
--
Gross Profit
148,655.00
-69,422.00
18,934.00
36,772.00
66,616.00
Operating Expense
270,967.00
285,438.00
365,376.00
272,228.00
204,153.00
Operating Income
-122,312.00
-354,860.00
-346,442.00
-235,456.00
-137,537.00
Net Non Operating Interest Income Expense
-219,854.00
-130,001.00
-90,526.00
-114,538.00
-100,513.00
Other Income Expense
-320,547.00
-166,188.00
-114,679.00
200,796.00
-53,720.00
Pretax Income
-662,713.00
-651,049.00
-551,647.00
-149,198.00
-291,770.00
Tax Provision
-44,332.00
-99,318.00
-38,067.00
-47,694.00
-121,726.00
Net Income Common Stockholders
-618,381.00
-551,731.00
-513,580.00
-101,504.00
-170,044.00
Diluted NI Available to Com Stockholders
-618,381.00
-551,731.00
-513,580.00
-101,504.00
-170,044.00
Basic EPS
-2.65
-2.43
-2.60
-0.92
-1.54
Diluted EPS
-2.65
-2.43
-2.60
-0.92
-1.54
Basic Average Shares
240,603.79
227,256.47
197,530.77
110,673.31
110,673.31
Diluted Average Shares
279,408.02
227,256.47
197,530.77
243,649.51
243,649.51
Total Operating Income as Reported
-122,312.00
-354,860.00
-346,442.00
-235,456.00
-137,537.00
Total Expenses
429,081.00
446,294.00
429,471.00
272,228.00
204,153.00
Net Income from Continuing & Discontinued Operation
-618,381.00
-551,731.00
-513,580.00
-101,504.00
-170,044.00
Normalized Income
-323,426.42
-417,028.36
-409,225.14
-239,689.52
-131,927.05
Interest Income
3,578.00
4,823.00
912.00
19.00
215.00
Interest Expense
158,287.00
133,167.00
77,474.00
112,971.00
97,466.00
Net Interest Income
-219,854.00
-130,001.00
-90,526.00
-114,538.00
-100,513.00
EBIT
-504,426.00
-517,882.00
-474,173.00
-36,227.00
-194,304.00
EBITDA
-476,402.00
-493,672.00
-453,764.00
-18,031.00
-177,885.00
Reconciled Cost of Revenue
158,114.00
160,856.00
64,095.00
--
--
Reconciled Depreciation
28,024.00
24,210.00
20,409.00
18,196.00
16,419.00
Net Income from Continuing Operation Net Minority Interest
-618,381.00
-551,731.00
-513,580.00
-101,504.00
-170,044.00
Total Unusual Items Excluding Goodwill
-316,100.00
-159,035.00
-112,089.00
203,214.00
-52,215.00
Total Unusual Items
-316,100.00
-159,035.00
-112,089.00
203,214.00
-52,215.00
Normalized EBITDA
-160,302.00
-334,637.00
-341,675.00
-221,245.00
-125,670.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-21,145.42
-24,332.36
-7,734.14
65,028.48
-14,098.05
12/31/2020 - 6/16/2022
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TEVA.TA Teva Pharmaceutical Industries Limited
6,890.00
+0.89%
ITCI Intra-Cellular Therapies, Inc.
76.91
-1.83%
AMRX Amneal Pharmaceuticals, Inc.
8.47
-1.28%
PROC Procaps Group S.A.
1.9000
+0.53%
HCM HUTCHMED (China) Limited
20.85
-0.24%
CTLT Catalent, Inc.
60.18
-0.18%
PRGO Perrigo Company plc
25.85
+2.17%
TEVA Teva Pharmaceutical Industries Limited
18.18
+1.28%
ELAN Elanco Animal Health Incorporated
12.62
-2.70%
SUPN Supernus Pharmaceuticals, Inc.
33.67
-2.52%